The cost of integrated HIV care and buprenorphine/naloxone treatment: Results of a cross-site evaluation

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue SUPPL. 1, 2011, Pages

  Schackman, Bruce R ^a   Leff, Jared A ^a   Botsko, Michael ^b   Fiellin, David A ^c   Altice, Fredrick L ^c   Korthuis, P Todd ^d   Sohler, Nancy ^e   Weiss, Linda ^f   Egan, James E ^f   Netherland, Julie ^f   Gass, Jonathan ^f   Finkelstein, Ruth ^g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Center for HIV Educational Studies and Training   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Medicine and Department of Public Health and Preventative Medicine ^*  (United States)

^f CITY COLLEGE OF NEW YORK   (United States)

^g NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

buprenorphine naloxone; cost; HIV; integrated care; opioid dependency; substance abuse

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ARTICLE; FUNDING; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; OPIATE ADDICTION; PATIENT CARE; PATIENT TRANSPORT; PHYSICIAN; PRIORITY JOURNAL; REIMBURSEMENT; URINALYSIS;

ANTI-HIV AGENTS; BUPRENORPHINE; DELIVERY OF HEALTH CARE, INTEGRATED; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 79951802651     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820a9a66     Document Type: Article

References (29)

1. Altice FL, Sullivan LE, Smith-Rohrberg D, et al. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis. 2006;43 (Suppl 4):S178-S183. (Pubitemid 44901885)
2. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006; 43(Suppl 4):S184-S190. (Pubitemid 44901886)
3. Parthasarathy S, Weisner CM. Five-year trajectories of health care utilization and cost in a drug and alcohol treatment sample. Drug Alcohol Depend. 2005;80:231-240. (Pubitemid 41427637)
4. Weisner C, Mertens J, Parthasarathy S, et al. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA. 2001; 286:1715-1723. (Pubitemid 33010257)
5. Basu S, Smith-Rohrberg D, Bruce RD, et al. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis. 2006;42:716-721. (Pubitemid 43271389)
6. Ettner SL, Huang D, Evans E, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"? Health Serv Res. 2006;41:192-213.
7. Sindelar JL, Fiellin DA. Innovations in treatment for drug abuse: solutions to a public health problem. Annu Rev Public Health. 2001;22:249-272. (Pubitemid 32452507)
8. Schackman BR, Merrill JO, McCarty D, et al. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43(Suppl 4):S247-S253. (Pubitemid 44901892)
9. Weiss L, Egan JE, Botsko M, et al. A multi-site evaluation of integrated buprenorphine/naloxone and HIV treatment: overview of the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S1-S2.
10. Cheever LW, Kresina TF, Cajina A, et al. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S3-S6.
11. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
12. US Department of Labor Bureau of Labor Statistics. National compensation survey. Available at: http://data.bls.gov. Accessed August 14, 2009.
13. American Society of Addiction Medicine. New online buprenorphine training program announced. Available at: http://www.jointogether.org/ news/yourturn/announcements/2006/new-online-buprenorphine.html. Accessed September 2, 2009.
14. Murray L, ed. Red Book. Montvale, NJ: Thomson PDR; 2008.
15. Cacciola JS, Alterman AI, McLellan AT, et al. Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. Drug Alcohol Depend. 2007;87:297-302. (Pubitemid 46217911)
16. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1): S77-S90. (Pubitemid 34013693)
17. Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/ naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S68-S75.
18. Mark TL, Kassed CA, Vandivort-Warren R, et al. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99:345-349.
19. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http://www. accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed November 16, 2009.
20. Jones ES, Moore BA, Sindelar JL, et al. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009; 99:132-140.
21. Zarkin GA, Dunlap LJ, Homsi G. The substance abuse services cost analysis program (SASCAP): a new method for estimating drug treatment services costs. Evaluation and Program Planning. 2004;27:35-43. (Pubitemid 37551534)
22. Pcssmentor.org. Physician clinical support system-Buprenorphine. Available at: http://www.pcssbuprenorphine.org/pcss/index.php. Accessed November 16, 2009.
23. McCollister KE, French MT, Pyne JM, et al. The cost of treating addiction from the client's perspective: results from a multi-modality application of the Client DATCAP. Drug Alcohol Depend. 2009;104:241-248.
24. Olmstead TA, Sindelar JL, Petry NM. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend. 2007;87:175-182. (Pubitemid 46215922)
25. Sindelar JL, Olmstead TA, Peirce JM. Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs. Addiction. 2007;102:1463-1471. (Pubitemid 47246989)
26. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104:982-992.
27. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/nalox-one treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22-S32.
28. Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS. 2008;22:1345-1354.
29. Zarkin GA, Dunlap LJ, Hicks KA, et al. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005; 14:1133-1150. (Pubitemid 41645377)